BCDA News and Press, BioCardia Inc. From 08/24/22

SUNNYVALE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock’s cell therapy product candidates for the treatment of heart failure u...

BioCardia, Inc. (BCDA) Q2 2022 Earnings Conference Call August 10, 2022, 04:30 PM ET Company Participants Jules Abraham - IR, CORE IR Peter Altman - President and CEO David McClung - CFO Conference Call Participants Kumaraguru Raja - Brookline Capital...

BioCardia press release ( NASDAQ: BCDA ): Q2 GAAP EPS of -$0.14 (vs. -$0.20 Y/Y). Revenue of $0.97M (+1285.7% Y/Y). Shares +0.67% . For further details see: BioCardia Q2 GAAP loss per share narrows, revenue up

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2022 and filed its quarterly r...

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and six months e...

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clini...

SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

BioCardia (NASDAQ:BCDA) on Wednesday said it had been granted a U.S. patent for its imaging system for targeting cardiac therapies. Sunnyvale, Calif.-based BCDA is a developer of cellular and cell-derived therapies for the treatment of cardiovascular and pulmonary diseases. The U.S. Patent Of...

SUNNYVALE, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,...

BioCardia, Inc. (BCDA) Q1 2022 Earnings Conference Call May 11, 2022 04:30 PM ET Company Participants Jules Abraham - Investor Relations, CORE IR Peter Altman - President & Chief Executive Officer David McClung - Chief Financial Officer Conference Call Participants Kumaraguru Raja - Brook...